Breakthrough's comment on research suggesting a combination of drug treatments could stop tumour growth

Research by scientists at the University of Sheffield suggests that the combination of zoledronic acid (a drug used to prevent bone loss) and chemotherapy agent doxorubicin could stop the growth of breast cancer tumours.

Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says:

"Breakthrough welcomes any research which investigates new uses for existing treatments to help benefit people with breast cancer.

"However, it's important to remember that this research is at a very early stage and further studies are needed before we will know whether this type of approach will be an effective treatment for women with breast cancer. We await further developments in this area with interest."